High lipophilicity and high daily dose of oral medications are associated with significant risk for drug‐induced liver injury

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Hepatology

• Publication date

  2013-07-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1002/hep.26208PMID 23258593
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• R: A language and environment for statistical computing.

  2014cited by this paper
• Is toxicogenomics a more reliable and sensitive biomarker than conventional indicators from rats to predict drug-induced liver injury in humans?

  2012cited by this paper
• A decade of toxicogenomic research and its contribution to toxicological science.

  2012cited by this paper
• FDA-approved drug labeling for the study of drug-induced liver injury.

  2011cited by this paper
• Risk factors for idiosyncratic drug-induced liver injury.

  2010cited by this paper
• Lipophilicity in drug discovery

  2010cited by this paper
• Back to basics for idiosyncratic drug-induced liver injury: dose and metabolism make the poison.

  2010cited by this paper
• Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events

  2010cited by this paper
• Developing structure-activity relationships for the prediction of hepatotoxicity.

  2010influential reference
• The Liver Toxicity Biomarker Study: Phase I Design and Preliminary Results

  2009cited by this paper
• Evaluations of the trans-sulfuration pathway in multiple liver toxicity studies.

  2009cited by this paper
• Defining optimum lipophilicity and molecular weight ranges for drug candidates-Molecular weight dependent lower logD limits based on permeability.

  2009cited by this paper
• Pharmacological Promiscuity: Dependence on Compound Properties and Target Specificity in a Set of Recent Roche Compounds

  2009cited by this paper
• Physicochemical drug properties associated with in vivo toxicological outcomes: a review

  2009cited by this paper
• 3.3 Trovafloxacin: a case study of idiosyncratic or iatrogenic liver toxicity – molecular mechanisms and lessons for pharmacotoxicity

  2009cited by this paper
• Physiochemical drug properties associated with in vivo toxicological outcomes.

  2008cited by this paper
• Relationship between daily dose of oral medications and idiosyncratic drug‐induced liver injury: Search for signals

  2008cited by this paper
• The role of early in vivo toxicity testing in drug discovery toxicology.

  2008cited by this paper
• The influence of drug-like concepts on decision-making in medicinal chemistry

  2007cited by this paper
• Mechanisms of trovafloxacin hepatotoxicity: studies of a model cyclopropylamine-containing system.

  2007cited by this paper
• Drug treatments for obesity: orlistat, sibutramine, and rimonabant.

  2007cited by this paper
• Drug hepatotoxicity from a regulatory perspective.

  2007cited by this paper
• Combinatorial QSAR Modeling of P-Glycoprotein Substrates

  2006cited by this paper
• Role of Metabolism in Drug-Induced Idiosyncratic Hepatotoxicity

  2005cited by this paper
• Results of a Prospective Study of Acute Liver Failure at 17 Tertiary Care Centers in the United States

  2002cited by this paper
• Prediction of a new drug's potential to cause idiosyncratic reactions.

  2001cited by this paper
• Statistical computing

  2000cited by this paper
• Drug-induced liver disease.

  2000cited by this paper
• Concordance of the toxicity of pharmaceuticals in humans and in animals.

  2000cited by this paper
• Ibuprofen-induced hepatotoxicity in patients with chronic hepatitis c: a case series

  1998cited by this paper
• Diclofenac‐associated hepatotoxicity: Analysis of 180 cases reported to the food and drug administration as adverse reactions

  1995cited by this paper
• Drug induced liver disease.

  1983cited by this paper

• Emerging methods to improve PROTAC transport across cell membrane

  2026cites this paper
• AI-driven virtual screening platform identifies novel NSUN2 inhibitor candidates for targeted cancer therapy: a computational drug discovery approach

  2026cites this paper
• A Cationic Amphiphilic Drug (CAD) Defense System in the Nematode Caenorhabditis elegans

  2026cites this paper
• Anticancer activity promoted by ligand diversity in diiron thiocarbyne complexes.

  2025cites this paper
• Transforming Treatment: The Impact of Bariatric Surgery on Oral Drug Absorption.

  2025cites this paper
• NLRP3 Inflammasome Inhibition by the Novel Bispecific Antibody InflamAb Attenuates Atherosclerosis in Apolipoprotein E–Deficient Mice

  2025cites this paper
• Drug metabolizing enzymes and transporters, and their roles for the development of drug-induced liver injury

  2025cites this paper
• In-depth understanding of the structure-based reactive metabolite formation of organic functional groups

  2025cites this paper
• Mechanisms of drug induced liver injury

  2025influential citation
• Eleven new metabolites of fluvoxamine detected in the solid tissues and body fluids obtained from a deceased overdosed with fluvoxamine in vivo, and the metabolites in the human liver microsomes in vitro using LC-HR–MS/MS

  2025cites this paper
• Machine Learning for Toxicity Prediction Using Chemical Structures: Pillars for Success in the Real World

  2025cites this paper
• Industry Perspective on Nonclinical Approaches for Hepatotoxicity Risk Assessment: Insights from Two Longitudinal Surveys Conducted in 2023 and 2017.

  2025cites this paper
• Randomized phase 2a trial assessing a novel septin molecular glue in Alzheimer's disease

  2025cites this paper
• VitroBert: modeling DILI by pretraining BERT on in vitro data

  2025cites this paper
• Developmental neurotoxicity evaluation of di(2-ethylhexyl) phthalate (DEHP) and three alternative plasticizers in human neurospheres.

  2025cites this paper
• Integration of In Vitro and In Silico Approaches Enables Prediction of Drug-Induced Liver Injury

  2025influential citation
• Assessment of liver injury potential of investigational medicines in drug development.

  2025cites this paper
• From mechanisms to medicine: Ferroptosis as a Therapeutic target in liver disorders

  2025cites this paper
• Discovery of Pre-Clinical Candidate VU6008055/AF98943: A Highly Selective, Orally Bioavailable, and Structurally Distinct Tricyclic M4 Muscarinic Acetylcholine Receptor Positive Allosteric Modulator (PAM) with Robust In Vivo Efficacy

  2025cites this paper
• Discovery of novel non-sulfonylurea NLRP3 inflammasome inhibitors for the treatment of multiple inflammatory diseases.

  2025cites this paper
• Recent advances in AI-based toxicity prediction for drug discovery

  2025cites this paper
• High-throughput screening for drug-induced hepatotoxicity using Biochemical assays

  2025cites this paper
• Flavan-3-gallate catechins in green tea (Camellia sinensis) reduce amiodarone solubility and dissolution in fasted state simulated intestinal fluid

  2025cites this paper
• Temporal Distribution Shift in Real-World Pharmaceutical Data: Implications for Uncertainty Quantification in QSAR Models

  2025cites this paper
• Comprehensive analysis of high-throughput transcriptomics to distinguish drug-induced liver injury (DILI) phenotypes

  2025cites this paper
• Evaluating the synergistic use of advanced liver models and AI for the prediction of drug-induced liver injury

  2025cites this paper
• Unraveling the Role of CYP2E1 in Antitubercular Drug–Induced Hepatotoxicity: From Molecular Mechanisms to Clinical Implications

  2025cites this paper
• The Effect of Prophylactic Hepatoprotective Therapy on Drug-Induced Liver Injury in Patients Undergoing Chemotherapy for Cervical Cancer: A Retrospective Analysis Based on Propensity Score Matching

  2025cites this paper
• Liver injury related to vascular endothelial growth factor tyrosine kinase inhibitors: a pharmacovigilance analysis of the USA FDA adverse event reporting system (FAERS) database.

  2025cites this paper
• Epidemiology and Risk Determinants of Drug‐Induced Liver Injury: Current Knowledge and Future Research Needs

  2024cites this paper
• Prediction of bioactive compounds hepatotoxicity using in silico and in vitro analysis

  2024cites this paper
• Hepatotoxicity of antipsychotics: an exploratory pharmacoepidemiologic and pharmacodynamic study integrating FAERS data and in vitro receptor-binding affinities

  2024cites this paper
• Prediction of adverse drug reactions using demographic and non-clinical drug characteristics in FAERS data

  2024cites this paper
• Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update

  2024cites this paper
• Toxicological mechanisms and molecular impacts of tire particles and antibiotics on zebrafish.

  2024cites this paper
• Drug interaction with UDP-Glucuronosyltransferase (UGT) enzymes is a predictor of drug-induced liver injury

  2024cites this paper
• 1,3,5-Triaza-7-phosphaadamantane and Cyclohexyl Groups Impart to Di-Iron(I) Complex Aqueous Solubility and Stability, and Prominent Anticancer Activity in Cellular and Animal Models.

  2024cites this paper
• Phytochemistry, pharmacology, toxicology and detoxification of Polygonum multiflorum Thunb.: a comprehensive review

  2024cites this paper
• Novel clinical phenotypes, drug categorization, and outcome prediction in drug-induced cholestasis: Analysis of a database of 432 patients developed by literature review and machine learning support.

  2024cites this paper
• The ameliorating effect of Rutin on hepatotoxicity and inflammation induced by the daily administration of vortioxetine in rats

  2024cites this paper
• A comprehensive analysis of liver safety across zibotentan oncology trials: knowledge of the past offers new perspectives on the present

  2024cites this paper
• Multi-view uncertainty deep forest: An innovative deep forest equipped with uncertainty estimation for drug-induced liver injury prediction

  2024cites this paper
• FETPY: a Diiron(I) Thio-Carbyne Complex with Prominent Anticancer Activity In Vitro and In Vivo.

  2024cites this paper
• Illuminating Potential of Diphenyltin(IV) Dithiocarbamate Compounds for Pharmacological Applications: Synthesis, Structural Elucidation, In-silico and Cytotoxicity Study on A549 Human Lung Cancer Cells

  2024cites this paper
• Generation of a drug-induced renal injury list to facilitate the development of new approach methodologies for nephrotoxicity.

  2024cites this paper
• Age-related differences in drug-induced liver injury: a retrospective single-center study from a large liver disease specialty hospital in China, 2002–2022

  2024cites this paper
• InterDILI: interpretable prediction of drug-induced liver injury through permutation feature importance and attention mechanism

  2024cites this paper
• Exploring the latest breakthroughs in rhodesain inhibitors for African trypanosomiasis

  2024cites this paper
• Review article: Recommendations for detection, assessment and management of suspected drug‐induced liver injury during clinical trials in oncology patients

  2024cites this paper
• Anticancer potential of NSAID-derived tris(pyrazolyl)methane ligands in iron(II) sandwich complexes.

  2024cites this paper
• Physiological liver microtissue 384-well microplate system for preclinical hepatotoxicity assessment of therapeutic small molecule drugs

  2024cites this paper
• Higher risk of hepatotoxicity associated with cabozantinib in cancer patients.

  2024cites this paper
• Discovery of Potent, Specific, and Orally Available NLRP3 Inflammasome Inhibitors Based on Pyridazine Scaffolds for the Treatment of Septic Shock and Peritonitis.

  2024cites this paper
• Collaborative SAR Modeling and Prospective In Vitro Validation of Oxidative Stress Activation in Human HepG2 Cells

  2023cites this paper
• Medicinal chemistry strategies targeting NLRP3 inflammasome pathway: A recent update from 2019 to mid-2023.

  2023cites this paper
• Hydrophobic tag-based protein degradation: Development, opportunity and challenge.

  2023cites this paper
• Novel Sulfonylurea-Based NLRP3 Inflammasome Inhibitor for Efficient Treatment of Nonalcoholic Steatohepatitis, Endotoxic Shock, and Colitis.

  2023cites this paper
• Chemistry-Based Modeling on Phenotype-Based Drug-Induced Liver Injury Annotation: From Public to Proprietary Data

  2023cites this paper
• Pharmacology of a Potent and Novel Inhibitor of the NOD-Like Receptor Pyrin Domain-Containing Protein 3 (NLRP3) Inflammasome that Attenuates Development of Nonalcoholic Steatohepatitis and Liver Fibrosis

  2023cites this paper
• Yin/Yang associated differential responses to Psoralea corylifolia Linn. In rat models: an integrated metabolomics and transcriptomics study

  2023cites this paper
• An original donor-dependent spheroid system for the prediction of idiosyncratic drug-induced liver injury risk

  2023cites this paper
• 4-hydroxylonchocarpin and corylifol A: The potential hepatotoxic components of Psoralea corylifolia L.

  2023cites this paper
• AI/ML Models to Predict the Severity of Drug-Induced Liver Injury for Small Molecules.

  2023cites this paper
• Preclinical evaluation of chemically reactive metabolites and mitigation of bioactivation in drug discovery.

  2023cites this paper
• Systematic Review and Meta-Analysis: Comparing Hepatocellular and Cholestatic Patterns of Drug Induced Liver Injury

  2023cites this paper
• JT002, a small molecule inhibitor of the NLRP3 inflammasome for the treatment of autoinflammatory disorders

  2023cites this paper
• Susceptibility to Hepatotoxic Drug-Induced Liver Injury Increased After Traumatic Brain Injury in Mice

  2023cites this paper
• Unveiling the therapeutic promise of natural products in alleviating drug‐induced liver injury: Present advancements and future prospects

  2023influential citation
• Mitochondrion-targeted antioxidant SkQ1 prevents rapid animal death caused by highly diverse shocks

  2023cites this paper
• Drug-induced liver injury: a comprehensive review

  2023cites this paper
• Estimating drug-induced liver injury risk by in vitro molecular initiation response and pharmacokinetic parameters for during early drug development.

  2023cites this paper
• Three-Dimensional Cell Co-Culture Liver Models and Their Applications in Pharmaceutical Research

  2023cites this paper
• Biocomputational-mediated screening and molecular docking platforms for discovery of coumarin-derived antimelanogenesis agents

  2023cites this paper
• An updated patent review of GPR40/ FFAR1 modulators (2020 – present)

  2023cites this paper
• Current and future strategies for targeting the endothelin pathway in cardiovascular disease

  2023cites this paper
• Industry Review of Best Practices for Risk Management of Drug-Induced Liver Injury from Development to Real-World Use

  2023cites this paper
• Drug-induced liver injury: An overview and update

  2023cites this paper
• Open Macromolecular Genome: Generative Design of Synthetically Accessible Polymers

  2023cites this paper
• The Structure-property Relationships of Clinically Approved Protease Inhibitors.

  2023cites this paper
• Development of binary classification models for assessment of drug-induced liver injury in humans using a large set of FDA-approved drugs.

  2022cites this paper
• The interactions between DNA nanostructures and cells: A critical overview from a cell biology perspective.

  2022cites this paper
• Early Drug-Induced Liver Injury (DILI) Risk Screening: "Free", as good as it gets.

  2022cites this paper
• Study on the Characteristics of Small-Molecule Kinase Inhibitors-Related Drug-Induced Liver Injury

  2022influential citation
• Assessment of a 3D neural spheroid model to detect pharmaceutical-induced neurotoxicity.

  2022influential citation
• Protein-Ligand Identification and In Vitro Inhibitory Effects of Cathine on 11 Major Human Drug Metabolizing Cytochrome P450s

  2022cites this paper
• In vitro and In silico studies of interactions of cathinone with human recombinant cytochrome P450 CYP(1A2), CYP2A6, CYP2B6, CYP2C8, CYP2C19, CYP2E1, CYP2J2, and CYP3A5

  2022cites this paper
• Recent advancement in drug development of nitro(NO2)‐heterocyclic compounds as lead scaffolds for the treatment of Mycobacterium tuberculosis

  2022cites this paper
• Modifications of the Triaminoaryl Metabophore of Flupirtine and Retigabine Aimed at Avoiding Quinone Diimine Formation

  2022cites this paper
• Nonclinical Safety Signals in PharmaPendium Improve the Predictability of Human Drug-Induced Liver Injury.

  2022cites this paper
• Indian ayurvedic herb, Boerhaavia diffusa as BCPR inhibitor: The story behind the curtains

  2022cites this paper
• Assessing risks and mechanisms of idiosyncratic drug toxicity by fingerprints of cell signaling responses

  2022cites this paper
• A novel quantitative computer-assisted drug-induced liver injury causality assessment tool (DILI-CAT)

  2022cites this paper
• Clinical Pattern of Tolvaptan-Associated Liver Injury in Trial Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD): An Analysis of Pivotal Clinical Trials.

  2022cites this paper
• AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

  2022cites this paper
• Reliably Filter Drug-Induced Liver Injury Literature With Natural Language Processing and Conformal Prediction

  2022cites this paper
• Overcoming Preclinical Safety Obstacles to Discover (S)-N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-6-(methylamino)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide (GDC-2394): A Potent and Selective NLRP3 Inhibitor.

  2022cites this paper
• Incidence and risk factors of drug‐induced liver injury

  2022cites this paper
• Relationships between the Structure and Severe Drug-Induced Liver Injury for Low, Medium, and High Doses of Drugs.

  2022cites this paper
• Ceftriaxone-induced hepatotoxicity in patients with common medical infections in Qatar: A retrospective study

  2022cites this paper
• Evaluation of Anti-Candida albicans Activity and Release of Ketoconazole in PMMA-G-PEG 4000 Films

  2022cites this paper